SHH medulloblastomas upregulate EZH2, the catalytic subunit of the PRC2, suggesting a growth-promoting function [12], and EZH2 inhibition has been proposed as a medulloblastoma therapy [22]. Here, EZH2 is linked to medulloblastoma.